# Canadian Myeloma Research Group: Phase 2 study closed enrollment, 72 enrolled (Multiple Myeloma)

**Score:** 45/100

| Field | Value |
|---|---|
| Sponsor | Canadian Myeloma Research Group |
| Sponsor type | Academic and hospital |
| Study | A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM |
| NCT ID | NCT04786028 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Multiple Myeloma |
| Intervention types | drug |
| Target enrollment | 72 |
| Site countries | Canada |
| Posted | 2021-03-08 |
| Planned start | 2021-12-08 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-22 |
| Last update posted | 2026-10-22 |

## Why this score
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04786028). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.